Comparative Pharmacology
Head-to-head clinical analysis: NUFYMCO versus TIOCONAZOLE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NUFYMCO versus TIOCONAZOLE.
NUFYMCO vs TIOCONAZOLE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
NUFYMCO is a lipid-regulating agent. Its mechanism involves activation of peroxisome proliferator-activated receptor alpha (PPARα), leading to increased lipolysis and elimination of triglyceride-rich particles from plasma, and reduced VLDL production.
Inhibition of fungal CYP450-dependent 14α-demethylase, blocking ergosterol synthesis and disrupting fungal cell membrane integrity.
NUFYMCO is a proprietary combination product; standard adult dosing is one capsule (25 mg bempedoic acid/20 mg ezetimibe) orally once daily.
Topical: Apply 1% cream, lotion, or solution to affected area twice daily for 2-4 weeks. Vaginal: Insert 1 applicatorful of 6.5% ointment intravaginally at bedtime as a single dose.
None Documented
None Documented
Clinical Note
moderateTioconazole + Tranilast
"The risk or severity of adverse effects can be increased when Tioconazole is combined with Tranilast."
Clinical Note
moderateTioconazole + Tolfenamic acid
"The risk or severity of adverse effects can be increased when Tioconazole is combined with Tolfenamic acid."
Clinical Note
moderateTioconazole + Nimesulide
"The risk or severity of adverse effects can be increased when Tioconazole is combined with Nimesulide."
Clinical Note
moderateTioconazole + Risedronic acid
Terminal elimination half-life is 12-15 hours in healthy adults, allowing twice-daily dosing; prolonged to 24-36 hours in moderate renal impairment
Terminal elimination half-life is approximately 24–30 hours after topical application, reflecting slow systemic clearance of absorbed fraction.
Renal (60-70% as unchanged drug), biliary/fecal (20-30% as metabolites and unchanged drug)
Primarily fecal (minimally absorbed; <5% absorbed dose excreted renally as metabolites); topically applied tioconazole is largely unabsorbed.
Category C
Category A/B
Antifungal
Antifungal
"The risk or severity of adverse effects can be increased when Tioconazole is combined with Risedronic acid."